title: Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease.
abstract: BACKGROUND
  No definite conclusions can be drawn from available data on the accuracy of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to assess disease activity in Crohn's disease.
  
  
  OBJECTIVE
  Plasma sTREM-1 levels were correlated with disease activity markers in Crohn's disease.
  
  
  METHODS
  191 consecutive patients from a single referral centre (Nancy IBD cohort) were prospectively enrolled between June 1, 2005 and December 12, 2008. Plasma sTREM-1 levels were also assessed amongst 20 healthy controls.
  
  
  RESULTS
  The sTREM-1 was detectable in 87 Crohn's disease patients (46%). Plasma sTREM-1 level was higher in Crohn's disease patients (interquartile range, 0-356) than in healthy controls (interquartile range, 0-15.1; P=0.01). It was neither correlated with Crohn's disease activity index (r=0.05, P=0.56), C-reactive protein (r=0.06, P=0.53), nor with albumin (r=-0.041, P=0.66). Crohn's disease activity index, C-reactive protein and albumin median levels were similar between patients with positive sTREM-1 levels and those with undetectable sTREM-1 levels. Azathioprine (P=0.06), infliximab (P=0.68) and methotrexate (P=0.56) did not influence sTREM-1 levels.
  
  
  CONCLUSIONS
  Plasma sTREM-1 does not appear to be an accurate marker of disease activity in Crohn's disease and cannot be recommended for assessing disease activity in these patients.
authors.affiliation: INSERM U954, Université Henri Poincaré 1, Vandoeuvre-lès-Nancy, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Billioud
authors.forename: Sébastien
authors.initials: S
authors.lastname: Gibot
authors.forename: Frédéric
authors.initials: F
authors.lastname: Massin
authors.forename: Abderrahim
authors.initials: A
authors.lastname: Oussalah
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Chevaux
authors.forename: Nicolas
authors.initials: N
authors.lastname: Williet
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bronowicki
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Bigard
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Guéant
authors.forename: Laurent
authors.initials: L
authors.lastname: Peyrin-Biroulet
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D001379:Azathioprine / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003424:Crohn Disease / Q000097:blood* / Q000276:immunology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood* / Q000187:drug effects; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use; D011446:Prospective Studies; D011971:Receptors, Immunologic / Q000097:blood* / Q000187:drug effects; D012709:Serum Albumin / Q000378:metabolism; D012720:Severity of Illness Index; D000073871:Triggering Receptor Expressed on Myeloid Cells-1; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins; D011971:Receptors, Immunologic; D012709:Serum Albumin; C408842:TREM1 protein, human; D000073871:Triggering Receptor Expressed on Myeloid Cells-1; D002097:C-Reactive Protein; D000069285:Infliximab; D001379:Azathioprine; D008727:Methotrexate